Use of checkpoint inhibitors in liver transplant recipients

In spite of their major impact in cancer therapy, immune checkpoint inhibitors are considered to be contraindicated in liver transplant recipients due to fear of rejection and fatal liver failure. Nevertheless, an increasing number of instances of liver transplant recipients treated with checkpoint...

Full description

Saved in:
Bibliographic Details
Published in:United European Gastroenterology Journal 2018-08, Vol.6 (7), p.970-973
Main Authors: Munker, Stefan, De Toni, Enrico N
Format: Article
Language:English
Subjects:
Checkpoint inhibition
hepatocellular carcinoma
liver transplant recipients
liver transplantation
nivolumab
pembrolizumab
rejection
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In spite of their major impact in cancer therapy, immune checkpoint inhibitors are considered to be contraindicated in liver transplant recipients due to fear of rejection and fatal liver failure. Nevertheless, an increasing number of instances of liver transplant recipients treated with checkpoint inhibitors is being published. We reviewed the reports on 14 known cases of liver transplant recipients who underwent treatment with checkpoint inhibitors and discuss factors likely to determine susceptibility to organ rejection including the choice of the agent and the immunosuppression employed, the assessment of Programmed cell death 1 ligand 1 (PD-L1) status in liver graft biopsies, and the time of treatment initiation.
ISSN:2050-6406
2050-6414
DOI:10.1177/2050640618774631